1. Peptide Sciences goes dark

March 6, 2026: Peptide Sciences — widely considered the largest research peptide vendor in the United States — replaced its product catalog with a three-sentence notice announcing it had "made the decision to voluntarily shut down operations."

The Henderson, Nevada-based company had operated for more than a decade and, according to e-commerce analytics cited across industry coverage, was generating millions in monthly online sales. It sold BPC-157, TB-500, retatrutide, semaglutide, tirzepatide, and dozens of other peptides under "research use only" labels.

No FDA warning letter, DOJ indictment, or court order has been publicly tied to the closure, drawing speculation from industry observers. A smaller competitor, Science.bio, quietly closed the same way in January 2026.

Why it matters: Thousands of customers, clinics, and resellers suddenly held inventory whose provenance can no longer be verified through the original vendor. When a supplier abruptly shuts down, any COA (certificate of analysis) issued under its name becomes functionally unverifiable — a problem that takes time to resolve.

Sources: LumaLex Law analysis (March 13, 2026); Partnership for Safe Medicines enforcement tracker; USITC Investigation No. 337-TA-1386.

2. FDA sends 30 warning letters to telehealth firms

March 3, 2026: The FDA announced 30 simultaneous warning letters to telehealth companies marketing compounded GLP-1 drugs, accusing them of false or misleading claims that their products were "generic versions" of Wegovy, Ozempic, Mounjaro, or Zepbound, or contained the "same active ingredient." It was the second major wave of such letters — 55 had gone out in September 2025.

In announcing the action, FDA Commissioner Marty Makary said: "We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms — and taking swift action."

The March 3 letters were paired with a March 31 enforcement wave targeting seven peptide vendors directly, each cited for selling unapproved GLP-1, GLP-1/GIP, and triple-agonist products. The FDA specifically flagged the co-packaging of bacteriostatic water and syringes as evidence of intended human use.

Why it matters: The agency is no longer treating RUO (research use only) labeling as a defensible shield. For the first time, the FDA is publicly telegraphing that intended-use analysis, not product labeling, will drive enforcement — a shift that raises the bar on every link in the peptide supply chain.

Sources: FDA press release (March 3, 2026); FDA Warning Letter database — March 31, 2026 batch; RAPS regulatory coverage (April 7, 2026).

3. Novo Nordisk sues Hims & Hers; settles 28 days later

February 9, 2026: Novo Nordisk filed a patent-infringement suit in the U.S. District Court of Delaware against Hims & Hers, accusing the telehealth company of mass-compounding semaglutide "made with inauthentic API." Hims shares fell 18% in a single session.

Then on March 9, the two companies made a joint announcement: Novo voluntarily dismissed the lawsuit, and Hims agreed to sell branded Ozempic and Wegovy on its platform, stop mass-marketing compounded GLP-1s, and transition existing patients to FDA-approved products. Hims shares surged more than 40% on the news.

The dispute coincided with Strive Compounding Pharmacy's January 14 antitrust suit against both Lilly and Novo, alleging coordinated interference with compounders' payment processors and telehealth partners — the first time compounders have flipped the legal script on the manufacturers.

Why it matters: The economic rationale for compounded GLP-1s is contracting. The largest consumer-facing compounded-GLP-1 telehealth channel in the country has now pivoted to branded product. What remains of the compounded market will be smaller, more specialized, and under greater scrutiny — making documented identity, purity, and potency testing non-negotiable for any compounder that intends to survive.

Sources: Bloomberg — Novo sues Hims (Feb 9, 2026); CNBC — settlement (March 9, 2026); STAT News — Strive antitrust filing (Jan 14, 2026).

4. Utah physician federally indicted over Chinese peptide pipeline

April 1, 2026: Federal prosecutors unsealed an indictment against Dr. Justin Bradley Watkins, a 39-year-old osteopathic physician from Pleasant View, Utah, and owner of TruHealth Clinic. The charges: receipt in interstate commerce and delivery for pay of misbranded drugs with intent to defraud, plus aiding and abetting.

According to the DOJ, Watkins allegedly sourced peptides from China through a middleman supplier, then relabeled and sold them to more than 200 patients without disclosing that the products were not FDA-approved. The indictment lists an unusually comprehensive inventory: tirzepatide, semaglutide, retatrutide, cagrilintide, BPC-157, TB-500, ipamorelin, CJC-1295, GHK, GHK-Cu, and NAD+.

The indictment landed the same week U.S. Customs and Border Protection in Cincinnati announced it had intercepted more than 5,000 peptide parcels moving through roughly 300 "master carton" shipments from China between December 2025 and March 2026.

Why it matters: This is the first high-profile criminal prosecution of a licensed physician specifically tied to retatrutide. For clinicians, the message is blunt: sourcing and documentation are now prosecutorial evidence, and the identity of every vial dispensed needs to be verifiable by something more than a supplier's word.

Sources: DOJ U.S. Attorney's Office — District of Utah press release; Salt Lake Tribune (April 7, 2026); CBP Cincinnati press release.

5. FDA opens door to reclassifying peptides

February 27, 2026: HHS Secretary Robert F. Kennedy Jr. announced on Joe Rogan's podcast that he intended to move roughly 14 of the 19 peptides currently on the FDA's Category 2 "do not compound" list back to Category 1 — effectively reopening the legal domestic compounding pathway for substances including BPC-157, ipamorelin, thymosin alpha-1, Semax, CJC-1295, and MOTS-c.

The formal follow-through came on April 15, when the FDA published a Federal Register notice announcing that its Pharmacy Compounding Advisory Committee will meet July 23–24, 2026 to evaluate seven peptides for reclassification, with five more to follow before February 2027. Public comments close July 9.

Regulators outside the U.S. are moving in the opposite direction — Health Canada issued a public advisory on April 9 warning against unauthorized injectable peptides.

Why it matters: This is the most consequential regulatory inflection point in U.S. peptide policy in a decade. A legitimized domestic compounding pathway would pull volume out of the grey market — but it raises the stakes for what "pharmacy-grade" actually means. Without USP monographs for most of the peptides under review, the burden of proving identity, purity, and endotoxin limits will fall squarely on independent analytical testing.

Sources: STAT News — PCAC meeting announcement (April 15, 2026); Washington Post (April 15, 2026); NPR (March 26, 2026); ProPublica — peptide safety investigation; Health Canada advisory (April 9, 2026).

What comes next

The peptide industry's center of gravity is shifting from who sells to who can prove what they're selling. We'll keep tracking the July PCAC meeting, the SAFE Drugs Act's progress, the Watkins case, and the fallout from Peptide Sciences' closure. Subscribe for future editions.